Fungal infection in the organ transplant recipient;Le infezioni fungine nel trapiantato

Recenti Progressi in Medicina

Volumn 94, Issue 11, 2003, Pages 516-528

  Colomba, Claudia ^a   Antinori, Spinello ^a  

^a UNIVERSITY OF PALERMO   (Italy)

Author keywords

Fungal infection; Immunosuppression; Solid organ transplantation

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; FLUCONAZOLE; IMMUNOSUPPRESSIVE AGENT; ITRACONAZOLE; VORICONAZOLE;

ASPERGILLUS; BONE MARROW TRANSPLANTATION; CANDIDA; DIAGNOSTIC TEST; DISEASE COURSE; DRUG EFFICACY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MYCOSIS; ORGAN TRANSPLANTATION; PROPHYLAXIS; RECIPIENT; REVIEW;

ANTIFUNGAL AGENTS; ASPERGILLOSIS; BONE MARROW TRANSPLANTATION; CANDIDIASIS; HEART-LUNG TRANSPLANTATION; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSION; KIDNEY TRANSPLANTATION; MYCOSES; ORGAN TRANSPLANTATION; POSTOPERATIVE COMPLICATIONS; PRACTICE GUIDELINES; TRANSPLANTATION CONDITIONING;

EID: 0344099395     PISSN: 00341193     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (94)

1. De Repentigny L, Reiss E. Current trends in immunodiagnosis of candidiasis and aspergillosis. Rev Infect Dis 1984; 6: 301-12.
2. Herent P, Stynen D, Hernando F, Fruit J, Poulain D. Retrospective evaluation of two latex agglutination tests for detection of circulating antigens during invasive candidosis. J Clin Microbiol 1992; 30: 2158-64.
3. Verweij PE, Meis JFGM. Microbiological diagnosis of invasive fungal infections in transplant recipients. Transpl Infect Dis 2000; 2: 80-7.
4. van Deventer AJ, Goessens WH, van Belkum A, van Vliet HJ, Van Etten EE, Verbrugh HA. Improved detection of Candida albicans by PCR in blood of neutropenic mice with sistemic candidiasis. J Clin Microbiol 1995; 33: 625-8.
5. Chrissanthou E, Klingspor L, Tollemar J, et al. PCR and other non-culture methods for diagnosis of invasive Candida infection in allogenic bone marrow and solid organ transplant recipients. Mycoses 1999; 42: 239-47.
6. van Deventer AJ, Goessens WH, van Belkum A, van Vliet HJ, Van Etten EE, Verbrugh HA. PCR monitoring of response to liposomal amphotericin B treatment of systemic candidiasis in neutropenic mice. J Clin Microbiol 1996; 34: 25-8.
7. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30: 662-78.
8. Sobel JD. Practice guidelines for the treatment of fungal infections. Clin Infect Dis 2000;30:652.
9. th Annual meeting, New Orleans, September 2000.
10. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-66.
11. Williamson EC, Millar MR, Steward CG, et al. Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 1999; 104: 560-8.
12. Gordon SM, Avery RK. Aspergillosis in lung transplantation: incidence, risk factors, and prophylactic strategies. Transpl Infect Dis 2001; 3: 161-7.
13. Singh N, Arnow PM, Onham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64: 716-20.
14. th Annual Meeting of the Infectious Diseases Society of America (New Orleans). Alexandria, Virginia: Infectious Diseases Society of America, 2000: 261.
15. Anaissie EJ, Costa SF. Nosocomial aspergillosis is waterborne. Clin Infect Dis 2001; 33: 1546-8.
16. th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington: American society of microbiology, 2000: 375.
17. Geldreich EE. Biological profiles in drinking water. In: Microbial quality of water supply in distribution system. Boca Aton: CRC Lewis, 199: 103-58.
18. Arvanitidou M, Kanellou K, Constantidinides TC, et al. The occurrence of fungi in hospital and community potable waters. Lett Appl Microbiol 1999; 29: 81-4.
19. Hospenthal DR, Kwon-Chung KJ, Bennet JE. Concentrations of airborne Aspergillus compared to the incidence of invasive aspergillosis: lack of correlation. Med Mycol 1998; 36: 165-8.
20. Mahieu LM, De Dooy JJ, Van Laer FA, Jansens H, Ieven MM. A prospective study on factors influencing aspergillus spore load in the air during renovation works in a neonatal intensive care unit. J Hosp Infect 2000; 45: 191-7.
21. th Interscience Conference on Antimicrobial Agents and Chemotherapy (Toronto). Washington: American Society for Microbiology, 2000.
22. Naidu J, Singh SM. Aspergillus chevalieri (Mangin) Thom and Church: a new opportunistic pathogen of human cutaneous aspergillosis. Mycoses 1994; 37: 271-4.
23. Caillot D, Casasnovas O, Bernard A, et al. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol 1997; 15: 139-47.
24. Guillemain R, Lavarde V, Amrein C, Chevalier P, Guinvarc'h A, Glotz D. Invasive aspergillosis after transplantation. Transplant Proc 1995; 27: 1307-9.
25. Hopwood V, Johnson EM, Cornish JM, Foot AB, Evans EG, Warnock DW. Use of the Pastorex aspergillus antigen latex agglutination test for the diagnosis of invasive aspergillosis. J Clin Pathol 1995; 48: 210-3.
26. Rohrlich P, Sarfati J, Mariani P, et al. Prospective sandwich enzyme-linked immunosorbent assay for serum galactomannan: early predictive value and clinical use in invasive aspergillosis. Pediatr Infect Dis J 1996; 15: 232-7.
27. Sulahian A, Tabouret M, Ribaud P, et al. Comparison of an enzyme immunoassay and latex agglutination test for detection of galactomannan in the diagnosis of invasive aspergillosis. Eur J Clin Microbiol Infect Dis 1996; 15: 139-45.
28. Verweij PE, Dompenling EC, Donnelly JP, Schattenberg AV, Meis JF. Serial monitoring of Aspergillus antigen in the early diagnosis of invasive aspergillosis. Preliminary investigations with two examples. Infection 1997; 25: 86-9.
29. Viscoli C, Machetti M, Gazzola P, et al. Aspergillus galactomannan antigen in the cerebrospinal fluid of bone marrow transplant reciepients with probable cerebral aspergillosis. J Clin Microbiol 2002; 40: 1496-9.
30. Verweij PE, Latgè JP, Rijs AJMM, et al. Comparison of antigen detection and PCR assay using bronchoalveolar lavage fluid for diagnosing invasive pulmonary aspergillosis in patients receiving treatment for haematological malignancies. J Clin Microbiol 1995; 33: 3150-3.
31. Maertens J, Verhaegen J, Demuynck H, et al. Autopsy-controlled prospective evaluation of serial screening for circulating galactomannan by a sandwich enzyme-linked immunosorbent assay for haematological patients at risk for invasive Aspergillosis. J Clin Microbiol 1999; 37(10): 3223 8.
32. Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7-14.
33. Maertens J, Verhaegen J, Lagrou K, Van Eldere J, Boogaerts M. Screening for circulating galactomannan as a noninvasive diagnostic tool for invasive aspergillosis in prolonged neutropenic patients and stem cell transplantation recipients: a prospective validation. Blood 2001 15; 97: 1604-10.
34. Yamakami Y, Hashimoto A, Yamagata E, et al. Evaluation of PCR for detection of DNA specific for Aspergillus spp. In sera of patients with various forms of pulmonary aspergillosis. J Clin Microbiol 1998; 36: 3619-23.
35. Loeffler J, Hebart H, Brauchle U, Schumacher U, Einsele H. Comparison between plasma and whole blood specimens for detection of Aspergillus DNA by PCR. J Clin Microbiol 2000; 38: 3830-3.
36. Kami M, Fukui T, Ogawa S, et al. Use of real-time PCR on blood samples for diagnosis of invasive aspergillosis. Clin Infect Dis 2001; 33: 1504-12.
37. Stevens DA, Kan VL, Judson MA, et al. Practice guidelines for diseases caused by Aspergillus. Clin Infect Dis 2000; 30: 696-709.
38. Sepkowitz KA. Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002; 34: 1098-107.
39. Saag MS, Graybill RJ, Larsen RA, et al. Practice guidelines for the management of cryptococcal disease. Clin Infect Dis 2000; 30: 710-8.
40. Patterson JE. Epidemiology of fungal infections in solid organ transplant patients. Transpl Infect Dis 1999; 1: 229-36.
41. Villacian JS, Paya CV. Prevention of infections in solid organ transplant recipients. Transpl Infect Dis 1999; 1: 50-64.
42. van der Waaij D. Colonization resistance of the digestive tract: clinical consequences and implications. J Antimicrob Chemother 1982; 10: 263-70.
43. Wiesner RH, Hermans PE, Rakela J, et al. Selective bowel decontamination to decrease gram-negative aerobic bacterial and Candida colonization and prevent infection after orthotopic liver transplantation. Transplantation 1988; 45: 570-4.
44. Gorensek MJ, Carey WD, Washington JA 2nd, Vogt DP, Broughan TA, Westveer MK. Selective bowel decontamination with quinolones and nystatin reduces gram-negative and fungal infections in orthotopic liver transplant recipients. Cleve Clin J Med 1993; 60: 139-44.
45. Arnow PM, Carandang GC, Zabner R, Irwin ME. Randomized controlled trial of selective bowel decontamination for prevention of infections following liver transplantation. Clin Infect Dis 1996; 22: 997-1003.
46. Tollemar J, Ericzon BG, Holmberg K, Andersson J. The incidence and diagnosis of invasive fungal infections in liver transplant recipients. Transplant Proc 1990; 22: 242-4.
47. Wajszczuk CP, Dummer JS, Ho M, et al. Fungal infections in liver transplant recipients. Transplantation 1985; 40: 347-53.
48. Collins LA, Samore MH, Roberts MS, et al. Risk factors for invasive fungal infections complicating orthotopic liver transplantation. J Infect Dis 1994; 170: 644-52.
49. Castaldo P, Stratta RJ, Wood RP, et al. Fungal infections in liver allograft recipients. Transplant Proc 1991; 23: 1967.
50. Patel R, Portela D, Badley AD, et al. Risk factors of invasive Candida and non-Candida fungal infections after liver transplantation. Transplantation 1996; 62: 926-34.
51. Hadley S, Samore MH, Lewis WD, Jenkins RL, Karchmer AW, Hammer SM. Major infectious complications after orthotopic liver transplantation and comparison of outcomes in patients receiving cyclosporine or FK506 as primary immunosuppression. Transplantation 1995; 59: 851-9.
52. Winston DJ, Pakrasi A, Busuttil RW. Prophylactic fluconazole in liver transplant recipients. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1999; 131: 729-37.
53. Lumbreras C, Cuervas-Mons V, Jara P, et al. Randomized trial of fluconazole versus nystatin for the prophylaxis of Candida infection following liver transplantation. J Infect Dis 1996; 174: 583-8.
54. Badley AD, Seaberg EC, Porayko MK, et al. Prophylaxis of cytomegalovirus infection in liver transplantation: a randomised trial comparing a combination of ganciclovir and acyclovir to acyclovir. NIDDK Liver Transplantation Database. Transplantation 1997; 64: 66-73.
55. Paya CV. Fungal infections in solid-organ transplantation. Clin Infect Dis 1993; 16: 677-88.
56. Fisher NC, Singhal S, Miller SJ, Hastings JG, Mutimer DJ. Fungal infection and liposomal amphotericin B (AmBisome) therapy in liver transplantation: a 2 year review. J Antimicrob Chemother 1999; 43: 597-600.
57. Singh N, Arnow PM, Bonham A, et al. Invasive aspergillosis in liver transplant recipients in the 1990s. Transplantation 1997; 64: 716-20.
58. th annual meeting of the Infectious Diseases Society of America. (abstract J3) 1994.
59. Paterson DL, Singh N. Invasive aspergillosis in transplant recipients. Medicine (Baltimore) 1999; 78: 123-38.
60. Selby R, Ramirez CB, Singh R, et al. Brain abscess in solid organ transplant recipients receiving cyclosporine-based immunosuppression. Arch Surg 1997; 132: 304-10.
61. th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto 1997: 242.
62. Kanj SS, Welty-Wolf K, Madden J, et al. Fungal infections in lung and heart-lung transplant recipients. Report of 9 cases and review of the literature. Medicine (Baltimore) 1996; 75: 142-56.
63. Brooks RG, Hofflin JM, Jamieson SW, Stinson EB, Remington JS. Infectious complications in heart-lung transplant recipients. Am J Med 1985; 79: 412-22.
64. Cahill BC, Hibbs JR, Savik K, et al. Aspergillus airway colonization and invasive disease after lung transplantation. Chest 1997; 112: 1160-4.
65. Husni RN, Gordon SM, Longworth DL, et al. Cytomegalovirus infection is a risk factor for invasive aspergillosis in lung transplant recipients. Clin Infect Dis 1998; 26: 753-5.
66. Paradis IL, Williams P. Infection after lung transplantation. Semin Respir Infect 1993; 8: 207-15.
67. Westney GE, Kesten S, De Hoyos A, Chapparro C, Winton T, Maurer JR. Aspergillus infection in single and double lung transplant recipients. Transplantation 1996; 61: 915-9.
68. Goldfarb NS, Avery RK, Goormastic M, et al. Hypogammaglobulinemia in lung transplant recipients. Transplantation 2001; 71: 242-6.
69. Haug MT, Petrie J, Mehta A, et al. Lymphopenia as a marker of T-cell subset suppession induced by OKT3, ATGAM, azathioprine or mycophnolate treatment in lung transplan recipients. Los Angeles: American College of Clinical Pharmacy, 2000, November.
70. Paradowski LJ. Saprophytic fungal infections and lung transplantation-revisited. J Heart Lung Transplant 1997; 16: 524-31.
71. Kramer MR, Denning DW, Marshall SE, et al. Ulcerative tracheobronchitis after lung transplantation. A new form of invasive aspergillosis. Am Rev Respir Dis 1991; 144: 552-6.
72. Hamacher J, Spiliopoulos A, Kurt AM, Nicod LP. Pre-emptive therapy with azoles in lung transplant patients. Eur Respir J 1999; 13: 180-6.
73. Marr KA, Bowden RA. Fungal infections in patients undergoing blood and marrow transplantation. Transpl Infect Dis 1999; 1: 237-46.
74. Wakayama M, Shibuya K, Ando T, et al. Deep-seated mycosis as a complication in bone marrow transplantation patients. Mycoses 2002; 45: 146-51.
75. Kami M, Machida U, Okuzumi K, et al. Effect of fluconazole prophylaxis on fungal blood cultures: an autopsy-based study involving 720 patients with haematological malignancy. Br J Haematol 2002; 117: 40-6.
76. Marr KA, Seidel K, White TC, Bowden RA. Candidemia in allogeneic blood and marrow transplant recipients: evolution of risk factors after the adoption of prophylactic fluconazole. J Infect Dis 2000; 181: 309-16.
77. Abi-Said D, Anaissie E, Uzun O, Raad I, Pinzcowski H, Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin Infect Dis 1997; 24: 1122-8.
78. van Burik JH, Leisenring W, Myerson D, et al. The effect of prophylactic fluconazole on the clinical spectrum of fungal diseases in bone marrow transplant recipients with special attention to hepatic candidiasis. An autopsy study of 355 patients. Medicine (Baltimore) 1998; 77: 246-54.
79. Wald A, Leisenring W, van Burik JA, Bowden RA. Epidemiology of Aspergillus infections in a large cohort of patients undergoing bone marrow transplantation. J Infect Dis 1997; 175: 1459-66.
80. Schwarts S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomised multicenter trial. Blood 1999; 93: 3654-61.
81. Walsh TJ, Finberg RW, Arndt C, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. N Engl J Med 1999; 340: 764-71
82. Wingard J, White M, anaissie E, et al. A randomized double-blind comparative safety trial of Ambisome and Abelcet in febrile neutropenia patients. Focus on Fungal Infection; San Diego, 1999.
83. Fleming R, Kantarjlan H, Hushni R, et al. Randomized study of two formulations of amphotericin B in the treatment of suspected or documented fungal infection in patients with leukaemia. Focus on Fungal Infection; San Diego, 1999.
84. McWhinney PH, Kibbler CC, Hamon MD, et al. Progress in the diagnosis and management of aspergillosis in bone marrow transplantation: 13 years' experience. Clin Infect Dis 1993; 17: 397-404.
85. Williamson EC, Millar MR, Steward CG, et al. Infections in adults undergoing unrelated donor bone marrow transplantation. Br J Haematol 1999; 104: 560-8.
86. Wingard JR, Beals SU, Santos GN, Merz WG, Saral R. Aspergillus infections in bone marrow transplant recipients. Bone marrow transplant 1987; 2: 175-81.
87. Saugier-Veber P, Devergie A, Sulahian A, et al. Epidemiology and diagnosis of invasive pulmonary aspergillosis in bone marrow transplant patients: results of a 5 year retrospective study. Bone Marrow Transplant 1993; 12: 121-4.
88. Cofan F, Inigo P, Ricart MJ, et al. Invasive aspergillosis following kidney and kidney-pancreas transplantation. Nefrologia 1996; 16: 253-60.
89. Brown RS Jr, Lake JR, Katzman BA, et al. Incidence and significance of Aspergillus cultures following liver and kidney transplantation. Transplantation 1996; 61: 666-9.
90. Gallis HA, Berman RA, Cate TR, Hamilton JD, Gunnells JC, Stickel DL. Fungal infection following renal transplantation. Arch Intern Med 1975; 135: 1163-72.
91. Gustafson TL, Schaffner W, Lavely GB, Stratton CW, Johnson HK, Hutcheson RH. Invasive aspergillosis in renal transplant recipients: correlation with corticosteroid therapy. J Infect Dis 1983; 148: 230-8.
92. Millis SA, Seigler HF, Wolfe WG. The incidence and management of pulmonary mycosis in renal allograft patients. Ann Surg 1975; 182: 61.
93. Hesse UH, Sutherland DER, Najarian JS, Simmons RL. Intra-abdominal infections in pancreas transplant recipients. Ann Surg 1986; 203: 153-62.
94. Pekkins JD, Frohnert PP, Service FJ, et al. Pancreas transplantation at Mayo. III. Multidisciplinary management. Mayo Clin Proc 1990; 65: 496-508.